Bad News Teva Really Doesn't Need: A Potential Delay For Fremanezumab

One of Teva's few bright spots is its leading position in the big new commercial opportunity for migraine, but its CGRP drug fremanezumab could now be delayed by an issue at third-party manufacturer Celltrion.